ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Forecasted to Post FY2024 Earnings of $3.45 Per Share

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) – Stock analysts at Capital One Financial issued their FY2024 EPS estimates for shares of ANI Pharmaceuticals in a report issued on Wednesday, September 11th. Capital One Financial analyst T. Chiang expects that the specialty pharmaceutical company will post earnings of $3.45 per share for the year. The consensus estimate for ANI Pharmaceuticals’ current full-year earnings is $3.50 per share. Capital One Financial also issued estimates for ANI Pharmaceuticals’ Q4 2024 earnings at $0.92 EPS and FY2025 earnings at $3.88 EPS.

Other equities research analysts have also issued reports about the stock. StockNews.com lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Truist Financial reiterated a “hold” rating and set a $60.00 price target (down from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday, September 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $77.75.

ANI Pharmaceuticals Trading Up 6.9 %

Shares of ANIP opened at $60.06 on Monday. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of 37.53 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97. ANI Pharmaceuticals has a fifty-two week low of $48.20 and a fifty-two week high of $70.81. The firm has a 50 day moving average price of $61.27 and a 200-day moving average price of $63.85.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. The firm had revenue of $138.00 million during the quarter, compared to analyst estimates of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The business’s quarterly revenue was up 18.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.06 EPS.

Insider Activity at ANI Pharmaceuticals

In related news, COO Muthusamy Shanmugam sold 20,000 shares of the company’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $58.90, for a total transaction of $1,178,000.00. Following the completion of the sale, the chief operating officer now directly owns 682,620 shares in the company, valued at approximately $40,206,318. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 66,007 shares of company stock worth $4,089,790 in the last three months. 12.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Texas Permanent School Fund Corp increased its position in ANI Pharmaceuticals by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company’s stock valued at $912,000 after purchasing an additional 172 shares during the period. Louisiana State Employees Retirement System increased its position in ANI Pharmaceuticals by 2.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock valued at $490,000 after purchasing an additional 200 shares during the period. Arizona State Retirement System increased its position in ANI Pharmaceuticals by 4.7% during the 2nd quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock valued at $299,000 after purchasing an additional 211 shares during the period. Simplicity Wealth LLC increased its position in ANI Pharmaceuticals by 3.5% during the 2nd quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock valued at $429,000 after purchasing an additional 227 shares during the period. Finally, California State Teachers Retirement System increased its position in ANI Pharmaceuticals by 1.5% during the 1st quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock valued at $1,118,000 after purchasing an additional 233 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.